Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran Combined with Statins for Coronary Vulnerable Plaques
NCT06338293Phase 4Recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Mar 2024
- Primary completion
- Jun 2025
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 4 trial of inclisiran in coronary artery disease (CAD), sponsored by Nanjing First Hospital. Started Mar 2024; status: recruiting.
02
Drugs
inclisiran
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06338293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06338293.